|
1
|
Muniraj T, Jamidar PA and Aslanian HR:
Pancreatic cancer: a comprehensive review and update. Dis Mon.
59:368–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xi JJ: MicroRNAs in Cancer. Cancer Treat
Res. 158:119–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
6
|
Wang Z: Advances with microRNAs in
tumorigenesis and cancer therapy. Curr Pharm Des. 20:52452014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing AY, Wang B, Shi DB, et al:
Deregulated expression of miR-145 in manifold human cancer cells.
Exp Mol Pathol. 95:91–97. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu H, Xiao Z, Wang K, Liu W and Hao Q:
MiR-145 is down-regulated in human ovarian cancer and modulates
cell growth and invasion by targeting p70S6K1 and MUC1. Biochem
Biophys Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuse M, Nohata N, Kojima S, et al:
Restoration of miR-145 expression suppresses cell proliferation,
migration and invasion in prostate cancer by targeting FSCN1. Int J
Oncol. 38:1093–1101. 2011.PubMed/NCBI
|
|
10
|
Chiyomaru T, Enokida H, Tatarano S, et al:
miR-145 and miR-133a function as tumour suppressors and directly
regulate FSCN1 expression in bladder cancer. Br J Cancer.
102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung
adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang S, Bian C, Yang Z, et al: miR-145
inhibits breast cancer cell growth through RTKN. Int J Oncol.
34:1461–1466. 2009.PubMed/NCBI
|
|
13
|
Mees ST, Schleicher C, Mardin WA,
Senninger N, Colombo-Benkmann M and Haier J: Analyzing miRNAs in
ductal adenocarcinomas of the pancreas. J Surg Res. 169:241–246.
2011. View Article : Google Scholar
|
|
14
|
Papaconstantinou IG, Manta A, Gazouli M,
et al: Expression of microRNAs in patients with pancreatic cancer
and its prognostic significance. Pancreas. 42:67–71. 2013.
View Article : Google Scholar
|
|
15
|
O’Neill GM, Seo S, Serebriiskii IG, Lessin
SR and Golemis EA: A new central scaffold for metastasis: parsing
HEF1/Cas-L/NEDD9. Cancer Res. 67:8975–8979. 2007. View Article : Google Scholar
|
|
16
|
Izumchenko E, Singh MK, Plotnikova OV, et
al: NEDD9 promotes oncogenic signaling in mammary tumor
development. Cancer Res. 69:7198–7206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai EC: Micro RNAs are complementary to 3′
UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szafranska AE, Davison TS, John J, et al:
MicroRNA expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee EJ, Gusev Y, Jiang J, et al:
Expression profiling identifies microRNA signature in pancreatic
cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
21
|
Seo S, Ichikawa M and Kurokawa M:
Structure and function of cas-L and integrin-mediated signaling.
Crit Rev Immunol. 26:391–406. 2006. View Article : Google Scholar
|
|
22
|
Singh MK, Izumchenko E, Klein-Szanto AJ,
Egleston BL, Wolfson M and Golemis EA: Enhanced genetic instability
and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Cancer Res. 70:8907–8916. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang JX, Gao F, Zhao GQ and Zhang GJ:
Expression and clinical significance of NEDD9 in lung tissues. Med
Oncol. 29:2654–2660. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim M, Gans JD, Nogueira C, et al:
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis
gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Speranza MC, Frattini V, Pisati F, et al:
NEDD9, a novel target of miR-145, increases the invasiveness of
glioblastoma. Oncotarget. 3:723–734. 2012.PubMed/NCBI
|
|
26
|
Xue YZ, Sheng YY, Liu ZL, et al:
Expression of NEDD9 in pancreatic ductal adenocarcinoma and its
clinical significance. Tumour Biol. 34:895–899. 2013. View Article : Google Scholar
|
